A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin
NCT06112808
·
clinicaltrials.gov ↗
PHASE1
Phase
ACTIVE_NOT_RECRUITING
Status
300
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Melanoma
Interventions
DRUG:
BCD-263
DRUG:
Opdivo
Sponsor
Biocad